Cartesian Therapeutics, Inc. — Director's Dealing 2023

Nov 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2023-11-13

Reporting Person: Brunn Carsten (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-11-13	Common Stock	D	55000	$2.06	Disposed	728081	Direct
2023-11-13	Common Stock	D	13600	$2.06	Disposed	714481	Direct
2023-11-13	Common Stock	D	169725	$2.06	Disposed	544756	Direct
2023-11-13	Common Stock	D	282800	$2.06	Disposed	261956	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-13	Employee Stock Option (right to buy)	$6.03	D	1000000	Disposed	2028-11-30	Common Stock (1000000)	Direct
2023-11-13	Employee Stock Option (right to buy)	$2.20	D	330000	Disposed	2029-02-24	Common Stock (330000)	Direct
2023-11-13	Employee Stock Option (right to buy)	$1.75	D	400000	Disposed	2029-10-06	Common Stock (400000)	Direct
2023-11-13	Employee Stock Option (right to buy)	$2.30	D	600000	Disposed	2030-01-01	Common Stock (600000)	Direct
2023-11-13	Employee Stock Option (right to buy)	$2.84	D	75000	Disposed	2030-06-30	Common Stock (75000)	Direct
2023-11-13	Employee Stock Option (right to buy)	$2.99	D	670000	Disposed	2031-01-03	Common Stock (670000)	Direct
2023-11-13	Employee Stock Option (right to buy)	$4.32	D	163000	Disposed	2031-09-23	Common Stock (163000)	Direct
2023-11-13	Employee Stock Option (right to buy)	$3.31	D	1056100	Disposed	2032-01-02	Common Stock (1056100)	Direct
2023-11-13	Employee Stock Option (right to buy)	$1.13	D	1275000	Disposed	2033-01-01	Common Stock (1275000)	Direct

Footnotes

F1: This unvested restricted stock, which was granted on January 4, 2021, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for $113,300, representing $2.06 per share, the Cash-out Amount as applied in the Merger.

F2: This unvested restricted stock, which was granted on September 24, 2021, was canceled in the Merger, in exchange for $28,016, representing $2.06 per share, the Cash-out Amount as applied in the Merger.

F3: This unvested restricted stock, which was granted on January 3, 2022, was canceled in the Merger, in exchange for $349,633.50, representing $2.06 per share, the Cash-out Amount as applied in the Merger.

F4: This unvested restricted stock, which was granted on January 2, 2023, was canceled in the Merger, in exchange for $582,568, representing $2.06 per share, the Cash-out Amount as applied in the Merger.

F5: This option, which provided for vesting as to 25% of the shares on December 1, 2019 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.

F6: This option, which provided for vesting as to 25% of the shares on February 25, 2020 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.

F7: This option, which provided for vesting as to 50% of the shares on October 7, 2020 and the remaining 50% of the shares on October 7, 2021, was canceled in the Merger, in exchange for a cash payment of $124,000, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.

F8: This option, which provided for vesting as to 25% of the shares on January 2, 2021 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.

F9: This option, which provided for vesting as to 25% of the shares on July 1, 2021 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.

F10: This option, which provided for vesting as to 25% of the shares on January 4, 2022 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.

F11: This option, which provided for vesting as to 25% of the shares on September 24, 2022 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.

F12: This option, which provided for vesting as to 25% of the shares on January 3, 2023 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger.

F13: This option, which provided for vesting as to 25% of the shares on January 2, 2024 with the remainder of the shares vesting in 36 substantially equal monthly installments thereafter, was canceled in the Merger, in exchange for a cash payment of $1,185,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.